Kaiser Permanente Self-Management Program Reduces Risk of Heart Attack and Stroke

Subjects with diabetes in Kaiser Permanente management programs lowered blood pressure, blood sugar and blood lipid levels over a 10-year period, according to the Preventing Heart Attacks and Strokes Everyday (PHASE) study conducted among roughly 100,000 Kaiser patients…

TZD Update

Thiazolidinediones were hailed as wonder drugs when first released in 1997. Learn what recent research has to say about TZDs.

Helping Your Diabetes Patients Plan for Ramadan

Learn about the set of guidelines that provide a framework for discussing Ramadan with your diabetes patients and their families, which stress the importance of individualization and education within a diabetes management plan.

Introduction to the Diabetes and Ramadan Practical Guidelines from the IDF-DAR Alliance

Fasting during Ramadan can be challenging for patients with diabetes and can increase risk of health complications. Therefore, it is essential to educate patients regarding the importance of blood glucose monitoring, maintaining a balanced diet and avoiding strenuous exercise.

FDA Approves New Indication for Victoza

Learn about the medication Victoza and its new FDA approved indication to reduce cardiovascular risk in diabetes patients.

Assessment of Hypoglycemia

Symptoms attributable to hypoglycemia are nonspecific and commonly occur in the absence of hyperinsulinemia. It is important to document Whipple’s triad before embarking on a long and potentially costly evaluation.

Long-Term Diabetes Management Requires a Road Map

Creating a therapeutic plan at the time of Type 2 diabetes diagnosis is pretty easy: one recommends therapeutic lifestyle changes and metformin therapy. If the A1C does not reach goal, the dose is increased and/or another agent is added. However, it is not always that simple. The plan needs to be individualized.

Application of the AACE 2017 Lipid Guidelines to Diabetes

The updated American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease were published in early 2017. Changes in the clinical practice guideline included the introduction of a new category of “extreme risk” and an expanded discussion of lipid management in people with diabetes.